Table 1.
Main features of SLE.
| Characteristics | Patient n°1 | Patient n°2 |
|---|---|---|
| Sex category | F | F |
| Age | 32 | 51 |
| Ethnicity | West African | Caucasian |
| Chronic medical illness | Glucose-6-phosphate dehydrogenase deficiency and Farh syndrome | Depression |
| Historical SLE features | ||
| Clinical involvement | Raynaud phenomenon, discoid lupus, and pericardial effusion | Disseminated discoid lupus, Raynaud phenomenon, and arthritis |
| Biological and immunological features | High titers of anti-nuclear antibodies, anti-dsDNA, anti-Sm, anti-SSA, and low C3 complement level | High titers of anti-nuclear antibodies, positive anti-dsDNA, anti-Sm, decreased C3 complement levels, and lymphopenia |
| Previous treatment for SLE | HCQ, CS, MTX, Thalidomide, Lenalidomide, Rituximab, ustekimumab, and Belimumab | HCQ, CS, Thalidomide, MTX, and Belimumab |
| Anifrolumab add-on treatment | HCQ 400 mg/day and CS 2 mg/day | HCQ 400 mg/day and CS 10 mg/day |
| SLE at antifrolumab initiation | ||
| SLE active manifestations | Disseminated active discoid lupus and alopecia | Disseminated active discoid lupus, arthritis, alopecia, and mucosal ulcers |
| SLEDAI-2k | 8 | 10 |
| CLASI-A | 23 | 35 |
| Response to anifrolumab at M6 | ||
| SLEDAI-2k | 2 | 2 |
| CLASI-A | 10 | 11 |
| COVID-19 | ||
| vaccination | 3 injections of mRNA BNT162b2 vaccine (reported) | 2 mRNA BNT162b2 injections and one mRNA-1273 vaccine |
| treatment At the time of vaccination | HCQ 400 mg/day, Belimumab 10 mg/kg/month (since 9 months), and CS 5 mg/day | HCQ 400 mg/day, Thalidomide 50 mg/day, CS 5 mg/day |
| sign Or symptoms | Cough, sore throat, and headache | Cough, sore throat, headache, and muscle pain |
| severitya | Mild illness | Mild illness |
| Serological SARS-CoV-2 results | ||
| Pre-anifrolumab | Neither anti-S nor anti-N antibodies | Anti-S antibodies |
| After SARS-CoV-2 infection | Anti-S and anti-N antibodies | Anti-S and anti-N antibodies |
CLASI; Cutaneous LE Disease Area and Severity Index, F; female, HCQ; hydroxychloroquine, MTX; methotrexate, CS: oral costicosteroid, N; nucleocapsid, NIH; National Institutes of Health S; spike, SLE; systemic lupus erythematosus, SLEDAI; Systemic Lupus Erythematosus Disease Activity Index.
aAdapted from NIH severity scale.